https://www.yiliao.com/index.php?action=history&feed=atom&title=PAM50
PAM50 - 版本历史
2026-04-18T03:48:41Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=PAM50&diff=316142&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-29T13:57:06Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>PAM50</strong>（Prediction Analysis of Microarray 50），商业名称为 <strong>Prosigna</strong>，是一种基于 nCounter 数字计数技术的乳腺癌多基因检测工具。它通过检测 <strong>50 个特征基因</strong>的表达水平，将乳腺癌精准地划分为四种<strong>固有亚型</strong>（Luminal A, Luminal B, HER2-enriched, Basal-like），并结合临床病理特征计算出<strong>复发风险评分 (ROR)</strong>。PAM50 是目前区分 Luminal A 型（预后好、化疗不获益）和 Luminal B 型（预后差、需化疗）的金标准方法，广泛用于绝经后激素受体阳性早期乳腺癌的辅助治疗决策。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">PAM50 / Prosigna</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Breast Cancer Intrinsic Subtyping (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心：四大固有亚型分类</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">检测参数</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">适用人群</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">绝经后 HR+/HER2- (LN 0-3)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">核心输出</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>固有亚型</strong> + <strong>ROR 评分</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">检测平台</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">nCounter (NanoString)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">基因数量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">50 个特征基因</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569;">独特优势</th><br />
<td style="padding: 6px 12px; color: #16a34a;"><strong>去中心化</strong>，生物学定性</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">科学原理：回归生物学本质</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
PAM50 的建立基于 Perou 和 Sørlie 提出的著名的<strong>“乳腺癌固有分子分型”</strong>理论。这 50 个基因被精心挑选出来，旨在最准确地将乳腺癌区分为具有不同生物学行为和预后的四大类：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>Luminal A 型：</strong> 激素受体高表达，增殖基因低表达。预后最好，对内分泌治疗极敏感，<strong>化疗通常无效</strong>。</li><br />
<li style="margin-bottom: 12px;"><strong>Luminal B 型：</strong> 增殖基因（如 <i>MKI67</i>, <i>CCNB1</i>）高表达。预后较差，<strong>需要化疗</strong>。</li><br />
<li style="margin-bottom: 12px;"><strong>HER2 富集型 (HER2-enriched)：</strong> 即使临床检测 HER2 为阴性，部分患者基因层面仍表现为 HER2 信号通路激活。</li><br />
<li style="margin-bottom: 12px;"><strong>基底样型 (Basal-like)：</strong> 多为三阴性乳腺癌，预后最差。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">ROR 评分：不仅看基因，还看淋巴结</h2><br />
<br />
<div style="background-color: #fff7ed; border-left: 5px solid #ea580c; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<p style="margin: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
<strong>ROR (Risk of Recurrence) 评分</strong>（0-100分）是 PAM50 的最终输出形式。它不仅整合了 50 个基因的表达谱（分子分型），还纳入了<strong>肿瘤大小</strong>和<strong>淋巴结状态</strong>。<br />
</p><br />
</div><br />
<br />
<div style="overflow-x: auto; margin: 20px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f1f5f9; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 20%;">ROR 风险分组</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 40%;">临床意义</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">10年远处复发率 (DR)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #16a34a;">低危 (Low)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">预后极好，<strong>豁免化疗</strong>，无需延长内分泌治疗。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">&lt; 10%</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #b45309;">中危 (Intermediate)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">灰色地带，需结合患者意愿和年龄决策。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">10% - 20%</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #b91c1c;">高危 (High)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>建议化疗</strong>，且强烈建议<strong>延长内分泌治疗</strong>至 10 年。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">&gt; 20%</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">平台优势：去中心化的 nCounter</h2><br />
<br />
<div style="background-color: #f0f9ff; border-left: 5px solid #1e40af; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #1e40af; font-size: 1.1em;">无需把样本寄到美国</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
与 Oncotype DX 必须将组织样本寄送至美国中心实验室不同，Prosigna 试剂盒基于 <strong>NanoString nCounter</strong> 平台。这是一种直接数字计数技术，无需 PCR 扩增，稳定性极高。<br />
<br><strong>优势：</strong> 可以在任何具备该设备的<strong>本地医院病理科</strong>开展检测，周转时间短（几天内出结果），更适合全球推广。<br />
</p><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Parker JS, et al. (2009).</strong> <em>Supervised risk predictor of breast cancer based on intrinsic subtypes.</em> <strong>[[Journal of Clinical Oncology]]</strong>. <br><br />
<span style="color: #475569;">[点评]：PAM50 的奠基之作，正式定义了用于临床诊断的 50 个基因组合及其分型算法。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Gnant M, et al. (2014).</strong> <em>Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score.</em> <strong>[[Annals of Oncology]]</strong>. <br><br />
<span style="color: #475569;">[点评]：基于 ABCSG-8 试验数据，验证了 ROR 评分在预测远期复发方面的有效性，尤其是区分 Luminal A/B 的能力。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[3] <strong>Dowsett M, et al. (2013).</strong> <em>Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.</em> <strong>[[Journal of Clinical Oncology]]</strong>. <br><br />
<span style="color: #475569;">[点评]：TransATAC 研究，直接对比显示 PAM50 ROR 在预测淋巴结阳性患者的预后方面优于 Oncotype DX RS。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
乳腺癌分子分型 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">核心概念</td><br />
<td style="padding: 10px 15px; color: #334155;">[[固有亚型]] (Intrinsic Subtypes) • [[Luminal A]] • [[Luminal B]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">竞争产品</td><br />
<td style="padding: 10px 15px; color: #334155;">[[21基因检测]] (Oncotype DX) • [[EndoPredict]] • [[MammaPrint]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">技术平台</td><br />
<td style="padding: 10px 15px; color: #334155;">[[NanoString]] (nCounter) • [[数字计数]] • [[去中心化]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020